AR075594A1 - Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4 - Google Patents
Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4Info
- Publication number
- AR075594A1 AR075594A1 ARP100100532A ARP100100532A AR075594A1 AR 075594 A1 AR075594 A1 AR 075594A1 AR P100100532 A ARP100100532 A AR P100100532A AR P100100532 A ARP100100532 A AR P100100532A AR 075594 A1 AR075594 A1 AR 075594A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrarb
- group
- halogen
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Procedimientos para su preparacion, intermedios utiles en estos procedimientos, composiciones farmacéuticas que contienen dichos compuestos y su uso en terapia, para asma, como broncodilatador, antiinflamatorio, antialérgico, etc. Reivindicacion 1: Un compuesto de formula (1) o una sal del mismo en la que R1 se selecciona entre el grupo compuestos por (1), (2), (3), (4) y (5); (1) un grupo de formula (a) en la que A se selecciona entre el grupo compuesto por H, alquilo C1-6 opcionalmente sustituido con uno o más grupos -NRaRb, -ORc, -C(O)NRaRb, -C(O)ORc, heterociclilo, fenilo o heteroarilo; cicloalquilo C3-7 opcionalmente sustituido con un grupo C(O)ORc o -NRaRb; heterociclilo opcionalmente sustituido con uno o más alquilo C1-6, heteroarilo opcionalmente sustituido con uno o más halogeno o alquilo C1-6, -NRaRb, fenilo sustituido con un grupo -(CH2)pC(O)OH en el que p es 0, 1, 2, o 3, o -(CH2)7C(O)OH; (2) un grupo de formula (b) en la que B es alquilo C1-6, (3) -C(O)NRaRb o -CH2C(O)NRaRb; (4) -S(O)2NRaRb; (5) alcoxi C1-6 opcionalmente sustituido con NRaRb; Ra, Rb y Rc son independientemente H o alquilo C1-6; R2 es halogeno, alquilo C1-6, CF3, hidroxi o alcoxi C1-6; R3 es halogeno, CF3, hidroxi, alcoxi C1-6, CRdReOH o CHF2; donde Rd y Re son independientemente H o metilo; R4 es H, halogeno, alquilo C1-6 o CF3; R5 y R6 son independientemente H, halogeno o alquilo C1-6; y n es 0 o 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15570209P | 2009-02-26 | 2009-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075594A1 true AR075594A1 (es) | 2011-04-20 |
Family
ID=42110309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100532A AR075594A1 (es) | 2009-02-26 | 2010-02-24 | Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4 |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US8357716B2 (es) |
| EP (1) | EP2401270B1 (es) |
| JP (1) | JP5520969B2 (es) |
| KR (1) | KR20110128896A (es) |
| CN (1) | CN102388039B (es) |
| AR (1) | AR075594A1 (es) |
| AU (2) | AU2010217629A1 (es) |
| BR (1) | BRPI1013396A2 (es) |
| CA (1) | CA2753337A1 (es) |
| CL (1) | CL2011002103A1 (es) |
| CO (1) | CO6420342A2 (es) |
| DK (1) | DK2401270T3 (es) |
| DO (1) | DOP2011000272A (es) |
| EA (1) | EA021740B1 (es) |
| ES (1) | ES2439773T3 (es) |
| HK (1) | HK1159621A1 (es) |
| HR (1) | HRP20131174T1 (es) |
| IL (1) | IL214655A0 (es) |
| MA (1) | MA33132B1 (es) |
| MX (1) | MX2011008972A (es) |
| NZ (1) | NZ594641A (es) |
| PE (1) | PE20120307A1 (es) |
| PL (1) | PL2401270T3 (es) |
| PT (1) | PT2401270E (es) |
| RS (1) | RS53133B (es) |
| SG (1) | SG173768A1 (es) |
| SI (1) | SI2401270T1 (es) |
| SM (1) | SMT201400001B (es) |
| TW (1) | TW201041879A (es) |
| UY (1) | UY32464A (es) |
| WO (1) | WO2010097395A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010002098A (es) | 2007-08-31 | 2010-03-30 | Eisai R&D Man Co Ltd | Compuesto policiclico. |
| CN102333777B (zh) | 2009-02-26 | 2014-06-25 | 卫材R&D管理有限公司 | 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途 |
| US8703954B2 (en) | 2009-02-26 | 2014-04-22 | Eisai R&D Management Co., Ltd. | Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
| US8729260B2 (en) * | 2010-05-19 | 2014-05-20 | Savior Lifetec Corporation | Process for the preparation of carbapenem using cabapenem intermediates and recovery of cabapenem |
| WO2012025473A1 (en) * | 2010-08-24 | 2012-03-01 | Glaxo Group Limited | Cc.chemokine receptor 4 antagonists |
| JP6691869B2 (ja) * | 2014-02-20 | 2020-05-13 | コーネル ユニヴァーシティー | ファシンを阻害するための化合物及び方法 |
| MX2019001223A (es) | 2016-07-29 | 2019-11-11 | Flx Bio Inc | Moduladores de receptores de quimioquina y usos de los mismos. |
| US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| JOP20190192A1 (ar) * | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| WO2018187509A1 (en) | 2017-04-04 | 2018-10-11 | Flx Bio, Inc. | Heterocyclic compounds as chemokine receptor modulators |
| EP3609883B1 (en) * | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
| KR20200104291A (ko) | 2017-11-06 | 2020-09-03 | 랩트 테라퓨틱스, 인크. | 항암제 |
| CN110028501B (zh) * | 2018-01-12 | 2022-02-22 | 迈德欣国际有限公司 | 化合物及其制备方法和用途 |
| JP7355758B2 (ja) | 2018-01-26 | 2023-10-03 | ラプト・セラピューティクス・インコーポレイテッド | ケモカイン受容体調節剤及びその使用 |
| CN113893220A (zh) * | 2020-07-07 | 2022-01-07 | 迈德欣国际有限公司 | 鼻粘膜给药剂型和其应用 |
| US20230322741A1 (en) | 2022-04-06 | 2023-10-12 | Rapt Therapeutics, Inc. | Chemokine receptor modulators and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1572200B1 (fr) | 2002-12-12 | 2011-08-17 | Aventis Pharma S.A. | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
| FR2848554A1 (fr) * | 2002-12-12 | 2004-06-18 | Aventis Pharma Sa | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
| SE0301650D0 (sv) * | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
| WO2008089307A2 (en) * | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
-
2010
- 2010-02-24 DK DK10705594.9T patent/DK2401270T3/da active
- 2010-02-24 AU AU2010217629A patent/AU2010217629A1/en not_active Abandoned
- 2010-02-24 PE PE2011001557A patent/PE20120307A1/es not_active Application Discontinuation
- 2010-02-24 TW TW099105340A patent/TW201041879A/zh unknown
- 2010-02-24 CA CA2753337A patent/CA2753337A1/en not_active Abandoned
- 2010-02-24 PT PT107055949T patent/PT2401270E/pt unknown
- 2010-02-24 MX MX2011008972A patent/MX2011008972A/es active IP Right Grant
- 2010-02-24 SI SI201030466T patent/SI2401270T1/sl unknown
- 2010-02-24 US US13/202,139 patent/US8357716B2/en not_active Expired - Fee Related
- 2010-02-24 SG SG2011059813A patent/SG173768A1/en unknown
- 2010-02-24 ES ES10705594.9T patent/ES2439773T3/es active Active
- 2010-02-24 MA MA34179A patent/MA33132B1/fr unknown
- 2010-02-24 US US12/711,283 patent/US8304446B2/en not_active Expired - Fee Related
- 2010-02-24 BR BRPI1013396A patent/BRPI1013396A2/pt not_active IP Right Cessation
- 2010-02-24 EP EP10705594.9A patent/EP2401270B1/en active Active
- 2010-02-24 UY UY0001032464A patent/UY32464A/es not_active Application Discontinuation
- 2010-02-24 KR KR1020117022518A patent/KR20110128896A/ko not_active Application Discontinuation
- 2010-02-24 EA EA201190142A patent/EA021740B1/ru not_active IP Right Cessation
- 2010-02-24 PL PL10705594T patent/PL2401270T3/pl unknown
- 2010-02-24 RS RS20130585A patent/RS53133B/en unknown
- 2010-02-24 AR ARP100100532A patent/AR075594A1/es not_active Application Discontinuation
- 2010-02-24 CN CN201080016319.3A patent/CN102388039B/zh not_active Expired - Fee Related
- 2010-02-24 JP JP2011551485A patent/JP5520969B2/ja not_active Expired - Fee Related
- 2010-02-24 WO PCT/EP2010/052307 patent/WO2010097395A1/en active Application Filing
- 2010-02-24 NZ NZ594641A patent/NZ594641A/xx not_active IP Right Cessation
-
2011
- 2011-08-15 IL IL214655A patent/IL214655A0/en unknown
- 2011-08-25 DO DO2011000272A patent/DOP2011000272A/es unknown
- 2011-08-26 CL CL2011002103A patent/CL2011002103A1/es unknown
- 2011-08-26 CO CO11109505A patent/CO6420342A2/es active IP Right Grant
-
2012
- 2012-01-04 HK HK12100042.4A patent/HK1159621A1/xx not_active IP Right Cessation
- 2012-10-02 US US13/633,382 patent/US8507543B2/en not_active Expired - Fee Related
-
2013
- 2013-12-10 HR HRP20131174AT patent/HRP20131174T1/hr unknown
-
2014
- 2014-01-03 SM SM201400001T patent/SMT201400001B/xx unknown
-
2016
- 2016-06-02 AU AU2016203684A patent/AU2016203684A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075594A1 (es) | Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4 | |
| AR091786A1 (es) | Inhibidores de la produccion de leucotrienos | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| ECSP14004812A (es) | Triazolopiridinas sustituidas | |
| AR098912A1 (es) | Inhibidores de syk | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR083543A1 (es) | Diamidas de amino-pirrolidin-azetidinas, composiciones farmaceuticas que las contienen y uso de las mismas para tratar dolores inflamatorios | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
| PE20151907A1 (es) | Compuestos y usos de estos para la modulacion de la hemoglobina | |
| PE20121431A1 (es) | Derivados de pirimidina como inhbidores de la enzima cinasa ptk2 | |
| PE20061298A1 (es) | Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR070535A1 (es) | Compuestos inhibidores de raf y metodos para usarlos | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| EA201100037A1 (ru) | Органические соединения | |
| AR074021A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| PE20131343A1 (es) | Derivados de acido benzoico | |
| ECSP11011185A (es) | Compuestos orgánicos | |
| UY32863A (es) | COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR | |
| AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| CR10654A (es) | Agentes que comprenden compuestos marcados con 18f y metodos relacionados | |
| AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
| AR084731A1 (es) | Derivados de imidazoquinolina sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |